OverviewSuggest Edit

Impel NeuroPharma is a pharmaceutical company that develops and commercializes therapies for patients suffering from central nervous system diseases. Its technology targets the vascular-rich upper nasal cavity and provides rapid absorption, consistent drug biodistribution. The company specializes in the treatment of such diseases as migraine, autism spectrum disorder, and Parkinson's disease.

TypePublic
Founded2008
HQSeattle, WA, US
Websiteimpelnp.com
Employee Ratings4.2

Latest Updates

Employees (est.) (May 2021)67(+10%)
Share Price (Sept 2021)$16(+6%)
Cybersecurity ratingAMore

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder and CSO
Adrian Adams

Adrian Adams

Chairman & CEO
John Leaman

John Leaman

Chief Financial Officer
Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer
Leonard S. Paolillo

Leonard S. Paolillo

Chief Commercial Officer
Lynn Gold

Lynn Gold

Senior VP of Regulatory
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, WA, US (HQ)
Waterfront Research Center, 201 Elliott Ave W #260
Show all (1)

Impel NeuroPharma Financials and Metrics

Impel NeuroPharma Revenue

USD

Net income (Q2, 2021)

(15.5m)

EBIT (Q2, 2021)

(14.9m)

Market capitalization (14-Sept-2021)

356.6m

Closing stock price (14-Sept-2021)

16.0
Impel NeuroPharma's current market capitalization is $356.6 m.
USDQ2, 2021

General and administrative expense

8.9m

R&D expense

6.1m

Operating expense total

14.9m

EBIT

(14.9m)
USDQ2, 2021

Total Equity

216.3m
USDQ2, 2021

Net Income

(26.8m)

Depreciation and Amortization

493.0k

Accounts Payable

1.1m

Cash From Operating Activities

(25.9m)
Show all financial metrics

Impel NeuroPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Impel NeuroPharma Online and Social Media Presence

Embed Graph

Impel NeuroPharma News and Updates

Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announce…

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space

Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021

Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021

SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today…

Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announ…
Show more

Impel NeuroPharma Blogs

Exploratory Efficacy of INP104 by Migraine Attack Severity and Time of Dosing: Results From the Phase 3 STOP 301 Study

Presented at PAINWeek Conference, September 7-11, 2021, Las Vegas, NV, USA Authors: Brian D. Loftus, MD, Michelle Murphy, PhD, Christopher J. Fitzpatrick, PhD, Sutapa Ray, Stephen B. Shrewsbury, MB ChB, Sheena K. Aurora, MD Purpose: It is increasingly recognized that oral drug delivery for the acute…

Improvements in Disability and the Interictal Period with INP104: Results from the Phase 3 STOP 301 Study

Presented at PAINWeek Conference, September 7-11, 2021, Las Vegas, NV, USA Authors: Dawn C. Buse, PhD, Cynthia E. Armand, MD, Robert Vann, PhD, Sutapa Ray, Stephen B. Shrewsbury, MB ChB, Sheena K. Aurora, MD Purpose: Migraine is a highly prevalent and debilitating condition. In 2016, it was estimate…

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

Timothy R. Smith MD; Paul Winner DO; Sheena K. Aurora MD; Maria Jeleva PhD; Jasna Hocevar- Trnka MD; Stephen B. Shrewsbury MB ChB Full manuscript can be accessed here: https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.14184 Objective: To report the safety, tolerability, explorato…

Impel NeuroPharma Announces Launch of Proposed Public Offering

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced t…

IMPEL NEUROPHARMA ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Cash Position and Extended Runway through 2022 Following $50 M…

Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

SEATTLE, August 9, 2021 — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will …
Show more

Impel NeuroPharma Frequently Asked Questions

  • When was Impel NeuroPharma founded?

    Impel NeuroPharma was founded in 2008.

  • Who are Impel NeuroPharma key executives?

    Impel NeuroPharma's key executives are John Hoekman, Adrian Adams and John Leaman.

  • How many employees does Impel NeuroPharma have?

    Impel NeuroPharma has 67 employees.

  • Who are Impel NeuroPharma competitors?

    Competitors of Impel NeuroPharma include Aerin Medical, Wuhan Orient Honest Medical and ReBio Technologies.

  • Where is Impel NeuroPharma headquarters?

    Impel NeuroPharma headquarters is located at Waterfront Research Center, 201 Elliott Ave W #260, Seattle.

  • Where are Impel NeuroPharma offices?

    Impel NeuroPharma has an office in Seattle.

  • How many offices does Impel NeuroPharma have?

    Impel NeuroPharma has 1 office.